mRNA vaccine targeting a malaria surface protein produces versatile antibodies

Antibodies to Merozoite Surface Protein 2 (PfMSP2) can promote multiple functions that may help clear malaria-causing merozoites.

• Malaria remains a significant global health issue with high morbidity and mortality.
• Current vaccines primarily target the sporozoite stage, offering limited protection in young children.
• There is a pressing need for vaccines that can target multiple stages of the malaria parasite's life cycle.
• Merozoites are critical for blood-stage replication and are linked to clinical malaria.
• The merozoite vaccine candidate PfMSP2 may stimulate protective antibody responses against malaria.

Simplified